These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Kottke T; Tonne J; Evgin L; Driscoll CB; van Vloten J; Jennings VA; Huff AL; Zell B; Thompson JM; Wongthida P; Pulido J; Schuelke MR; Samson A; Selby P; Ilett E; McNiven M; Roberts LR; Borad MJ; Pandha H; Harrington K; Melcher A; Vile RG Nat Commun; 2021 Mar; 12(1):1930. PubMed ID: 33772027 [TBL] [Abstract][Full Text] [Related]
25. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia. Betancourt D; Ramos JC; Barber GN J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177 [TBL] [Abstract][Full Text] [Related]
26. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308 [TBL] [Abstract][Full Text] [Related]
27. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers. Fehl DJ; Ahmed M Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863 [TBL] [Abstract][Full Text] [Related]
29. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908 [TBL] [Abstract][Full Text] [Related]
30. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Naik S; Nace R; Barber GN; Russell SJ Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623 [TBL] [Abstract][Full Text] [Related]
31. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179 [TBL] [Abstract][Full Text] [Related]
32. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma. Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639 [TBL] [Abstract][Full Text] [Related]
33. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity. Das K; Belnoue E; Rossi M; Hofer T; Danklmaier S; Nolden T; Schreiber LM; Angerer K; Kimpel J; Hoegler S; Spiesschaert B; Kenner L; von Laer D; Elbers K; Derouazi M; Wollmann G Nat Commun; 2021 Aug; 12(1):5195. PubMed ID: 34465781 [TBL] [Abstract][Full Text] [Related]
34. Combination of virotherapy with VSV and tumor vaccination significantly enhances the efficacy of antitumor therapy. Sobhanimonfared F; Bamdad T; Sadigh ZA; Nikoo HR; Choobin H Acta Virol; 2018; 62(4):394-400. PubMed ID: 30472869 [TBL] [Abstract][Full Text] [Related]
35. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis. Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245 [TBL] [Abstract][Full Text] [Related]
36. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein. Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969 [TBL] [Abstract][Full Text] [Related]
37. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. Kim DS; Dastidar H; Zhang C; Zemp FJ; Lau K; Ernst M; Rakic A; Sikdar S; Rajwani J; Naumenko V; Balce DR; Ewanchuk BW; Tailor P; Yates RM; Jenne C; Gafuik C; Mahoney DJ Nat Commun; 2017 Aug; 8(1):344. PubMed ID: 28839138 [TBL] [Abstract][Full Text] [Related]
38. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. Yarde DN; Nace RA; Russell SJ Exp Hematol; 2013 Dec; 41(12):1038-49. PubMed ID: 24067362 [TBL] [Abstract][Full Text] [Related]